Follow DNDi on LinkedInFollow DNDi on TwitterFollow DNDi on Facebook



NECT = Nifurtimox-Eflornithine Combination Therapy

NECT is the first new, improved treatment option in 25 years for stage 2 (advanced stage) human African trypanosomiasis (HAT) also known as sleeping sickness. It consists of a simplified coadministration of nifurtimox, which is given orally, and eflornithine, which is given intravenously.

  • Launched in 2009
  • Included  in the Essential Medicines List (EML) of the WHO since 2009
  • Much safer than Melarsoprol, a highly toxic, arsenic-based drug that kills 5% of treated patients, still used in 50% of patients.
  • Compared to eflornithine monotherapy, the best previously available treatment for stage 2 HAT, NECT is:
    • As effective
    • Safer
    • Easier to administer
    • More cost-effective
    • Requests shorter hospitalisation
  • The result of a six-year partnership between NGOs, governments, pharmaceutical companies, and the WHO.
  • Donated by Sanofi and Bayer Schering Pharma AG
  • Available in 12 African countries that account for 99% of reported HAT cases
  • Represents 93% of HAT treatments distributed  in DRC in 2011

Download NECT dossier in English [PDF 350KB]
Téléchargez le dossier NECT en français [PDF 317KB]
Read more about NECT project

  NECT News
Watch NECT video

On youtube!
- in English
- en français
Implementation progress
Available in 12 African countries

Request supply signed by Congo and Guinea
Recent Scientific Publications
PLos one, October 2012
Combination Therapy (NECT) for second stage gambiense
human African trypanosomiasis: MSF experience in the Democratic Republic of
the Congo

PLos NTDs, May 2010
NECT is Next: Implementing the new drug combination therapy for trypanosoma brucei gambiense Sleeping sickness

Except where otherwise noted, content on this site is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 2.5 Switzerland License